# Bactolife A/S

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bactolife-a-s

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.bactolife.com/
- Total disclosed funding: $68M
- Latest round: Series B (Jan 6, 2026)
- Investors on record: 5

## About

Based in Copenhagen, Denmark, and founded in 2017, Bactolife A/S is a company that offers a technology platform to develop Binding Proteins™, a biological solution for gut health. The company was co-founded by Mads Laustsen (CEO), Andreas H. Laustsen-Kiel (CTO), Sandra Wingaard Thrane (CSO), and Per Falholt (Board member). In January 2026, Bactolife A/S raised EUR 30 million in series B funding co-led by Cross-Border Impact Ventures and Export and Investment Fund of Denmark, along with Novo Holdings, Athos Service, and other unspecified investors also participated in the round.

Bactolife’s Binding Proteins™ provide specialty food/feed ingredients and dietary supplements to reduce the risk of gut health infections in humans and animals, without targeting growth or killing the bacteria directly but by neutralising the toxins produced by the harmful microbes. The firm’s solution can be incorporated into a wide variety of formulations, has highly versatile natural ingredients, and is stable with respect to temperature and pH resistance. Bactolife mainly serves mothers and children, the elderly, the immunodeficient, travellers, the deployed, and animal health.

Bactolife A/S generates revenues from B2B ingredient sales (Helm™) to CPG, dietary supplement, and animal nutrition partners, complemented by co-development/licensing partnerships and non-dilutive grants supporting platform development.

The company plans to utilize the January 2026 funding to further its clinical initiatives, increase manufacturing capacity, and get ready for upcoming product launches, beginning with an initial focus on the US market. The funding will enable Bactolife A/S to launch its first products under the ‘Helm’ brand in the US this year with expansion into Asia and Europe.

## Funding rounds

- Series B, Jan 6, 2026, $35M — Novo Holdings, Bill & Melinda Gates Foundation, Athos Capital, Cross-Border Impact Ventures, Export and Investment Fund of Denmark
- Series A, Aug 8, 2023, $33M — Novo Holdings, Bill & Melinda Gates Foundation, Athos Capital

## Investors

- Novo Holdings — Series A, Series B
- Bill & Melinda Gates Foundation — Series A, Series B
- Athos Capital (https://capitalatlas.ai/funds/athos-capital) — Series A, Series B
- Cross-Border Impact Ventures (https://capitalatlas.ai/funds/cross-border-impact-ventures) — Series B
- Export and Investment Fund of Denmark (https://capitalatlas.ai/funds/export-and-investment-fund-of-denmark) — Series B